Last reviewed · How we verify

Bilateral orchidectomy — Treatment Landscape & Competitive Intelligence

Bilateral orchidectomy (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Bilateral orchidectomy, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Androgel TESTOSTERONE Besins Hlthcare Androgen [EPC] Androgen receptor 1972-01-01
Testosteron Testosteron Gulhane School of Medicine Corticosteroid-binding globulin, Alpha-synuclein, Lanosterol 14-alpha demethylase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Besins Hlthcare · 1 drug in Bilateral orchidectomy
  2. Gulhane School of Medicine · 1 drug in Bilateral orchidectomy

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Bilateral orchidectomy:

Cite this brief

Drug Landscape (2026). Bilateral orchidectomy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/bilateral-orchidectomy. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing